Latest Articles

Publication Date
[Comparative analysis of clinicopathological and molecular characteristics between pure ovarian endometrioid carcinoma and synchronous endometrial and ovarian endometrioid carcinoma].

Objective: To investigate the differences in clinicopathological and molecular characteristics between pure ovarian endometrioid carcinoma (POEC) and synchronous endometrial and ovarian endometrioid carcinoma (SEOEC), aiming to provide a basis for …

Published: Jan. 31, 2026, midnight
Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology - Frontiers

Deep learning-based automated detection of endometrioid endometrial carcinoma in histopathology Frontiers

Published: Dec. 8, 2025, 10:41 a.m.
A Case Report of Endometrioid Carcinoma of the Ovary: A Comprehensive Clinical, Pathological, and Molecular Perspective.

Endometrioid carcinoma (EC) of the ovary represents a distinct subtype of epithelial ovarian cancers, comprising approximately 10%-20% of all ovarian malignancies. It is histologically similar to endometrial carcinoma of the …

Published: Dec. 8, 2025, midnight
A rare curious case of ureteric dissection in a patient with vaginal vault recurrence of endometrial carcinoma - SpringerOpen

A rare curious case of ureteric dissection in a patient with vaginal vault recurrence of endometrial carcinoma SpringerOpen

Published: Nov. 25, 2025, 8:52 a.m.
Mesonephric-like Adenocarcinoma (MLA) Diagnostic Criteria and Controversies: Perspectives and Guidance From Pathologists in the MLA Consortium.

Mesonephric-like adenocarcinoma (MLA) is a rare and aggressive gynecologic malignancy that has only been recognized in the last decade. It arises in the endometrium, ovaries, and other extrauterine sites (often …

Published: Nov. 24, 2025, midnight
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어

Published: Nov. 13, 2025, 5:50 a.m.
FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma Targeted Oncology

Published: Nov. 12, 2025, 7:08 p.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - BioSpace

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma BioSpace

Published: Nov. 12, 2025, 4:01 a.m.
Navigating Tumour Microenvironment in Endometrial Carcinoma: A Comprehensive Review Integrating Immunohistochemistry, Single-cell RNA-sequencing and Spatial Transcriptomics - Frontiers

Navigating Tumour Microenvironment in Endometrial Carcinoma: A Comprehensive Review Integrating Immunohistochemistry, Single-cell RNA-sequencing and Spatial Transcriptomics Frontiers

Published: Oct. 28, 2025, 4:44 p.m.
Ovarian mesonephric-like adenocarcinoma mimicking serous carcinoma: A case report integrating cytologic, frozen, histological, immunohistochemistry, and molecular analyses.

Mesonephric-like adenocarcinoma (MLA) is a recently recognized, rare subtype of endometrial carcinoma that can also arise in the ovary. Ovarian MLA is uncommon and often misdiagnosed due to its varied …

Published: Oct. 25, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!